Scott Moomaw Sells 20,533 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 20,533 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $768,550.19. Following the sale, the insider owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. The trade was a 11.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Scott Moomaw also recently made the following trade(s):

• On Monday, December 1st, Scott Moomaw sold 831 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total value of $26,749.89.

Liquidia Price Performance

Shares of LQDA stock opened at $39.99 on Thursday. The stock has a 50-day moving average price of $32.41 and a 200 day moving average price of $25.68. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of -27.77, a PEG ratio of 0.65 and a beta of 0.48. Liquidia Corporation has a 12 month low of $11.26 and a 12 month high of $40.53.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The company had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. Liquidia’s revenue was up 1106.7% on a year-over-year basis. Research analysts expect that Liquidia Corporation will post -1.51 EPS for the current year.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. NewEdge Advisors LLC acquired a new stake in Liquidia during the 2nd quarter worth $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Liquidia in the third quarter worth about $30,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia in the third quarter worth about $34,000. Steward Partners Investment Advisory LLC raised its position in shares of Liquidia by 24.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after purchasing an additional 4,927 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on Liquidia in a research report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research note on Tuesday, November 4th. Needham & Company LLC upped their price objective on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).